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1. Introduction 
Most humans have a relatively regular activity pattern (sleep, labor, and meal etc.). This 
activity can be roughly classified into the rest phase and active phase, and body 
temperature, heart rate, blood pressure, and the dominance of the sympathetic and 
parasympathetic nerves differ in each phase. These variations display daily rhythms, which 
are known as circadian rhythms.  
 
 
Fig. 1. Circadian rhythm of mouse leukocyte count  
For instance, ICR mice, which were housed under standardized light-dark cycle conditions 
(lights-on and lights-off at 7:00 and 19:00, respectively) at a room temperature of 24 ± 1oC 
(range) and a relative humidity of 60 ± 10% (range) and were allowed free access to food 
and water displayed a circadian rhythm in their leukocyte counts with a peak at noon and a 
trough at midnight (Fig. 1). Many organisms display rhythms in various factors (Table 1). In 
humans, heart rate and blood pressure decline at night. We spend much of our time in a 
standing position during the day and sleep in a recumbent position at night. It is thought 
that the wake-sleep transition and endogenous circadian rhythms are responsible for the 
circadian rhythms in heart rate and blood pressure. Circadian rhythms also exist for the 
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levels of hormones such as cortisol and melatonin (MLT). The plasma level of cortisol peaks 
in the morning and that of MLT peaks at midnight. Bone marrow cells, intestinal mucosal 
cells, and hair matrix cells show relatively active cell division. In the day, there is also a 
period of time when the number of cells is actively increased by segmentation (DNA 
synthesis) as well as a period of dormancy. The circadian rhythm of bone marrow cell 
division involves a peak in the evening and a trough in the midnight, and that of rectal 
mucosal cell division is higher at 7:00 and lower at 19:00. Thus, various factors in the living 
body have their own circadian rhythms, and the phases of these cycles vary for each factor.  
 
No. Factors Peak period Trough period Ref 
1 Body temperature 18:00-20:00 3:00-6:00 Lack et al., 2008 
2 Heart rate 8:00-18:00 4:00-6:00 Clarke et al., 1976 
3 Blood pressure 8:00-20:00 0:00-6:00 Degaute et al., 1991 
4 Hepatic blood flow 8:00 14:00 Lemmer et al., 1991 
5 Glomerular filtration 16:00 4:00 Koopman et al., 1989 
6 Lymphocytes 12:00-17:00 7:00 Miyawaki et al., 1984 
7 
Cortisol 
Adiponectin 
Leptin-binding protein 
8:00-13:00 
8:00-13:00 
8:00-14:00 
0:00-4:00 
2:00-4:00 
1:00-5:00 
Gavrila et al., 2003 
8 Melatonin 2:00-4:00 9:00-21:00 Kennaway et al., 1998 
9 
DNA synthesis in the 
bone marrow 
16:00 0:00 Smaaland et al., 1991 
10 
DNA synthesis in the 
rectal mucosa 7:00 19:00 Buchi et al., 1991 
Table 1. Circadian rhythms of various factors in humans 
 
No. Factors Peak period Trough period Ref 
1 
Spontaneous acute 
dissection and rupture 
of the thoracic aorta 
7:00-12:00 22:00-6:00 Gallerani et al., 1997 
2 Myocardial ischemia 8:00 0:00-4:00 Egstrup et al., 1991 
3 Ischemic stroke 8:00 18:00-6:00 Argentino et al., 1990 
4 
Subarachnoid 
hemorrhage 
6:00-20:00 0:00-4:00 Vermeer et al., 1997 
5 Asthma 2:00-5:00 7:00-19:00 Dethlefsen et al., 1985 
6 Temporal lobe epilepsy 15:00-21:00 0:00-5:00 Quigg et al., 1998 
7 Pain sensitivity in teeth 4:00-7:00 11:00-17:00 Pöllmann et al., 1978 
8 Migraine 4:00-10:00 21:00-1:00 Fox et al., 1998 
9 
Stiffness, pain, and 
functional disability in 
rheumatoid arthritis 
3:00-7:00 13:00-21:00 Straub et al., 2007 
Table 2. Circadian rhythms in the risk or frequency of disease occurrence 
These circadian rhythms are also associated with the risk or frequency of disease occurrence 
(Table 2). For example, asthma attacks get worse between midnight and early morning and 
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are seldom observed in the daytime (Fig.2; Dethlefsen et al., 1985). In addition, the risks of 
spontaneous acute dissection and rupture of the thoracic aorta, myocardial ischemia, 
ischemic stroke, and subarachnoid hemorrhage are higher during the active phase than 
during the rest phase. The variations in heart rate, blood pressure, and blood flow, etc., 
induced by the wake-sleep transition are considered to affect the risk of such problems 
occurring. Interestingly, pain such as toothache, migraine, and rheumatoid arthritis pain is 
more acute in the early morning. Collectively, circadian rhythms are recognized in many 
diseases, and certain time periods are associated with a high risk or frequency of disease 
occurrence. 
 
 
 
Fig. 2. Circadian rhythm of asthmatic attacks in asthma patients (redrawn from the data of 
Dethlefsen et al., 1985) 
Chronotherapy is defined as the administration of medications in accordance with biological 
rhythms in order to optimize therapeutic outcomes and/or control adverse effects, and it 
has been reported that many drugs such as antitumor drugs, antidepressants, and analgesic 
drugs show rhythm-dependent differences in their effects and pharmacokinetics (Tabuchi et 
al., 2005; Ushijima et al., 2005; Tampellini et al., 1998). These effects arise from the circadian 
rhythms found in elements of cellular physiology such as the cell cycle and the expression of 
receptors, hormones, and enzymes (Iurisci et al., 2006; Matsunaga et al., 2004; Koyanagi et 
al., 2006). Fig. 3 displays data for the dosing time-dependency of vomiting episodes in 
urogenital cancer patients treated with cisplatin (Kobayashi et al., 2001). Cisplatin (70 
mg/m2) was given to the patients at 5:00 or 17:00. After the cisplatin administration, all 
episodes of vomiting during a 6-hour period were recorded. Vomiting was markedly 
decreased in the patients treated at 17:00 compared with that at 5:00 (P = 0.061). 
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Fig. 3. Number of vomiting episodes according to the time (5:00 vs 17:00) of cisplatin 
administration in patients with urogenital cancer (redrawn from the data of Kobayashi et al., 
2001) 
 
 
Fig. 4. Circadian rhythm of plasma mevalonic acid levels and the influence of simvastatin 
dosing time on total cholesterol levels (redrawn from the data of Jones et al., 1992, and Saito 
et al., 1991) 
Moreover, it has been reported that circadian rhythms exist for asthma attacks and 
cholesterol synthesis, and medicinal treatment based on chronotherapy has been actively 
applied to the treatment of asthma, hypertension, and hyperlipidemia (D'Alonzo et al., 1995; 
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Hermida et al., 2010; Haus, 2007; Saito et al., 1991; Smolensky et al., 2007). Hydroxymethyl 
glutaryl coenzyme A (HMGCoA) reductase participates in the biosynthesis of mevalonic 
acid and is the rate-limiting enzyme of cholesterol biosynthesis. The plasma mevalonic acid 
levels in healthy volunteers showed a clear circadian rhythm, with higher levels seen at 
night and lower levels observed at daytime (Fig. 4A). Simvastatin is an HMGCoA reductase 
inhibitor. When simvastatin was administered to hyperlipidemic patients once a day in the 
morning or evening, the evening group displayed a significantly decreased total cholesterol 
level compared with the morning group (Fig. 4B). Thus, cholesterol biosynthesis may be 
effectively inhibited when simvastatin is administered in the evening, when the activity of 
HMGCoA reductase begins to increase. 
Taken together, many organisms display circadian rhythms in various factors, and 
chronotherapy that takes into account circadian rhythms is thought to be a useful 
therapeutic method.  
2. Chronobiology of rheumatoid arthritis 
Rheumatoid arthritis (RA) is an autoimmune disorder of unknown etiology and a chronic 
progressive disease that reduces the quality of life of individuals that suffer from the 
condition (Harris ED Jr., 1990; Gabriel SE., 2001). Although many requirements must be met 
to establish a diagnosis of RA, morning stiffness is a characteristic feature of RA (Arnett et 
al., 1988). Tumor necrosis factor- (TNF-), interleukin-1 (IL-1), and interleukin-6 (IL-6), 
which are inflammatory cytokines, show high concentrations in human blood and synovial 
fluid, and excess production of these cytokines plays a central role in the pathogenesis of RA 
(Feldmann et al., 1996; McInnes et al., 2005). Morning stiffness shows a circadian rhythm 
with a peak in the early morning in RA patients. The IL-6 concentration in blood also shows 
a circadian rhythm peaking from midnight to early morning, which mirrors the timing of 
morning stiffness (Crofford et al., 1997). 
In this chapter, I would like to introduce the circadian rhythm of rheumatoid arthritis and 
its mechanism. 
2.1 Circadian rhythm of rheumatoid arthritis 
RA is an autoimmune disorder of unknown etiology, and morning stiffness is a 
characteristic of the condition (Arnett et al., 1988). Pain, functional disability, and stiffness 
show circadian rhythms with a peak in the early morning in many RA patients (Fig. 5) 
(Bellamy et al., 1991; Kowanko et al., 1982), and the circadian rhythms of pain and stiffness 
may play a role in local and systemic inflammatory responses. Herold and Günther (Herold 
et al., 1987) reported that plasma C-reactive protein (CRP) levels, an indicator of 
inflammatory responses, showed a circadian rhythm with a peak in the early morning and a 
trough in the evening in RA patients, which matches the rhythms of pain and stiffness. 
Proinflammatory cytokines, such as TNF- and IL-6, are secreted from activated monocytes, 
and macrophages increase CRP levels in hepatocytes. There are clear circadian rhythms in 
the blood concentrations of these cytokines, with higher levels seen in the early morning in 
RA patients (Crofford et al., 1997; Perry et al., 2009). Since the circadian rhythms of CRP and 
cytokines are similar, it is considered that cytokine rhythms contribute to the rhythm of CRP 
levels. 
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Fig. 5. Circadian rhythms of stiffness, pain, and functional disability in RA patients 
(redrawn from the data of Strub et al., 2007) 
To clarify the relationship between the inflammatory response and cytokines in RA, we 
studied these circadian rhythms in RA model animals. MRL/lpr mice are an RA model that 
develop autoimmune disorders that share similarities with human RA and systemic lupus 
erythematosus (Abe et al., 1980; Koopman et al., 1988). It is difficult to monitor stiffness in 
RA model animals; however, the circadian rhythm of CRP was found to correspond to that 
of morning stiffness in RA patients (Herold et al., 1987). Using MRL/lpr mice, we estimated 
the plasma serum amyloid A (SAA) concentration, which is an acute-phase protein and a 
sensitive marker of acute inflammatory states, because the CRP level cannot be detected in 
mice. SAA is also synthesized in the liver upon stimulation by cytokines such as TNF- and 
IL-6 (Baumann et al., 1994; Gabay et al., 1999). Before RA onset, there was no significant 
circadian rhythm in plasma SAA levels (To et al., 2011). However, an obvious circadian 
rhythm in the plasma SAA concentration involving higher levels in the morning was 
observed in the MRL/lpr mice that developed RA. There was no significant circadian 
rhythm in plasma TNF- levels before RA onset (To et al., 2011). After RA onset, plasma 
TNF- levels showed an obvious daily variation, with higher levels in the morning and 
lower levels at midnight. Collagen-induced arthritis (CIA) represents a true autoimmune 
reaction against major joint components that is associated with class II major 
histocompatibility complex genes and pannus formation. CIA model animals display 
similarities with RA in terms of pathology, immunology, and genetics (Wooley et al., 1984; 
Holmdahl et al., 1989). It was previously reported that CIA mice showed increased 
cytokines levels, similar to RA patients (Marinova-Mutafchieva et al., 1997; Mussener et al., 
1997). In CIA mice, the SAA level was increased compared with that in the control group 
and showed a significant circadian rhythm involving higher levels in the morning after RA 
onset (Fig. 6). The plasma TNF- concentration also showed a circadian rhythm with a peak 
in the morning (Fig. 6) (To et al., 2009).  
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Fig. 6. Circadian rhythm of plasma SAA and TNF- levels in CIA mice (redrawn from the 
data of To et al., 2009) 
In healthy humans, there is no significant circadian rhythm in plasma IL-6 levels. Moreover, 
no circadian rhythm is found in patients with various other inflammatory connective tissue 
diseases. Only RA patients show a clear circadian rhythm in plasma IL-6 concentrations, 
with higher levels seen from night to early morning and lower levels observed during the 
daytime (Crofford et al., 1997; Arvidson et al., 1994). Therefore, it is considered that the 
circadian rhythm in plasma IL-6 levels, which is not present before RA, is a phenomenon 
peculiar to RA because identical results were obtained in RA patients and RA model 
animals. 
Collectively, the synchronization of the circadian rhythms of the inflammatory response and 
cytokine levels was also observed in RA patients and RA model animals. It is thought that 
the inflammatory response contributes to morning stiffness in RA because pain and stiffness 
develop in the early morning, when the CRP level is higher. Therefore, it is thought that the 
circadian rhythms of inflammatory cytokines play important roles in the expression of RA 
symptoms and that these rhythms are important for diagnosing RA. 
2.2 Factors affecting the circadian rhythm of rheumatoid arthritis 
Although the causes of the cytokine circadian rhythms generated by RA onset have not been 
completely clarified, it is thought that the MLT and cortisol balance and clock genes are 
involved in the mechanism. 
The circadian rhythms of mammals are mediated by the transcriptional/ posttranscriptional 
machinery regulating the clock genes including Clock, Bmal 1, period, and Cryptochrome (Cry) 
(Sato et al., 2006). Hashiramoto et al. reported that Cry, which is one of the clock genes, 
contributes to the induction of arthritis and increases the serum TNF- level (Hashiramoto 
et al., 2010). In this study, the number of activated CD3(+) CD69(+) T cells was significantly 
increased among lymphocytes from Cry1-/-Cry2- mice. Cry1-/-Cry2- mice display aggravated 
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arthritis and increased serum TNF- concentrations compared with wild type mice. Thus, 
Cry may play an important role in the inducement of RA.  
Cutolo et al. proposed that the balance between MLT and cortisol is related to the formation 
of cytokine circadian rhythms (Straub et al., 2007; Cutolo et al., 2003). MLT has an 
immunoenhancing effect and induces cytotoxic properties in monocytes etc. (Morrey et al., 
1994). Additionally, MLT enhances the expression of inflammatory cytokines (Garcia-
Mauriño et al., 1997). In contrast, glucocorticoid suppresses the expression of cytokines such 
as IL-1, IL-6, and TNF-. In humans, the MLT level in plasma shows a circadian rhythm 
with a peak at 3:00 (Kennaway et al., 1998), and the plasma cortisol level shows a circadian 
rhythm with higher levels seen at 8:00 (Miyatake et al., 1980). The secretion of MLT and 
cortisol in RA patients differs from that in healthy subjects; i.e., the serum MLT levels of RA 
patients peak about 2 hours earlier than those in healthy controls (Sulli et al., 2002). 
Furthermore, the peak cortisol level was found to be lower in RA patients than in the 
controls (Neeck et al., 1990). These changes in the hormone balance may contribute to the 
increased cytokine expression seen in RA. It was reported that the serum cytokine and MLT 
concentrations also showed circadian rhythms with peaks from midnight to early morning, 
which mirror those of morning stiffness (Arvidson et al., 1997; Sulli et al., 2002). Thus, MLT 
may be involved in the circadian rhythm of RA symptoms. 
We studied the corticosterone concentrations in MRL/lpr mice before/after RA onset. The 
corticosterone concentration before RA onset showed a significant circadian rhythm with 
higher levels during the early dark phase and lower levels during the period from the late 
dark phase to the early light phase (Fig. 7). After RA onset, there was a clear circadian 
rhythm in the corticosterone level. As rodents are nocturnal animals, the phases of their 
circadian rhythm for glucocorticoid secretion are shifted by about 12 hours compared with 
those for humans (Koyanagi et al., 2006). At 21:00, when the corticosterone level peaked, the 
corticosterone level after RA onset had decreased by 40.9% compared with that before RA 
onset (Fig. 7). The change in corticosterone secretion in the MRL/lpr mice was similar to 
that seen in RA patients. On the other hand, the MLT levels in rodents displayed a circadian 
rhythm with a peak at midnight, as is seen in humans (Conti et al., 1998). 
 
 
Fig. 7. Circadian rhythms of the corticosterone levels of MRL/lpr mice 
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Fig.8 shows a hypothesis for the interaction of cytokines and the secretion of MLT and 
glucocorticoid. Cytokine overexpression is controlled by the secretion balance between the 
circadian rhythms of MLT and corticosterone. However, the secretion of glucocorticoid 
declines in RA, and the induction of cytokine expression is increased by MLT. 
Consequently, the cytokine circadian rhythm follows that of MLT. The phases of the 
circadian rhythm for glucocorticoid and leukocyte counts, etc., differ by about 12 hours 
between humans and rodents. However, the phases of the circadian rhythms for the 
inflammatory response and cytokines are similar between humans and rodents. This may be 
caused by the similar circadian rhythms for MLT levels between human and rodents. 
Therefore, it is thought that the circadian rhythm and balance of MLT, which induces the 
expression of cytokines, and glucocorticoid, which suppresses their expression, participate 
in the circadian rhythm of RA symptoms. 
 
 
Fig. 8. Interaction of cytokines and the secretion of MLT and glucocorticoid 
3. Chronotherapy for rheumatoid arthritis 
In the treatment of RA, non-steroidal anti-inflammatory drugs (NSAID) are used to decrease 
pain; steroids are used to reduce pain and inflammation; and disease modifying 
antirheumatic drugs (DMARD) are used prior to the development of destructive changes in 
bones, joints, and organ tissues. In addition, biological DMARD can be used to target 
specific cytokines. 
In this Chapter, I summarize the chronopharmacology and chronotherapies of these drugs. 
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3.1 NSAID and glucocorticoids 
Arthritis develops in many RA patients. Thus, NSAID such as indomethacin are often used 
as analgesics. Levi et al. reported on the use of chronotherapy involving indomethacin for 
osteoarthritis (Levi et al., 1985). The patients with osteoarthritis took an indomethacin 
sustained-release (ISR) oral preparation once a day at 8:00, noon, or 20:00. The evening 
dosing protocol showed higher safety than the morning dosing protocol.  
Glucocorticoids have been used in RA therapy to treat symptoms such as joint stiffness and 
joint pain. Generally, glucocorticoids are administered in the morning according to the 
circadian rhythm of endogenous glucocorticoids. De Silva et al. performed a double-blind 
cross-over study to determine the effect of the timing of prednisolone administration on 
morning stiffness (De Silva et al., 1984). The duration of morning stiffness was markedly 
shorter in the night (22:00- 23:00) dosing group than in the morning (6:00- 7:00) dosing 
group. Moreover, Arvidson et al. also reported that the 2:00-treated group displayed a 
markedly decreased duration of morning stiffness and joint pain and reduced serum IL-6 
levels compared with the 7:30-treated group (Arvidson et al., 1997). From these results, it is 
thought that administering glucocorticoids at night is useful for the treatment of RA. 
Interesting evidence has been reported for glucocorticoid chronotherapy in recent years. 
Buttgereit et al. developed a new modified-release formulation of prednisone that releases 
prednisone about 4 hours after ingestion (Buttgereit et al., 2008). When RA patients were 
randomly given a modified-release tablet at bedtime or an immediate-release prednisone 
tablet in the morning, the relative change in the duration of joint morning stiffness was 
significantly higher with the modified-release tablet than with the immediate-release tablet. 
Furthermore, administering the modified-release prednisone at night did not change the 
patients' adrenocortical function over 12 months (Alten et al., 2010). These results show that 
chronotherapy with a modified-release prednisone tablet is safe and effective as a treatment 
for RA therapy, even though it was thought that administering glucocorticoids at night 
would have negative effects upon the circadian rhythm of endogenous cortisol and reduce 
hypothalamic-pituitary-adrenal axis function. Therefore, chronotherapy using the modified-
release prednisone tablet is considered to be a useful RA therapy. 
3.2 Methotrexate 
Methotrexate (MTX) is one of the most commonly used DMARD. It inhibits cytokine 
production by suppressing lymphocyte proliferation (Williams et al., 2001) and TNF- 
transcriptional activity (Becker et al., 1998). MTX induces a high American College of 
Rheumatology improvement response rate (Choi et al., 2002), inhibits joint inflammation 
(Kremer et al., 1992; Weinblatt et al., 1992), and conveys a marked survival benefit (Choi et 
al., 2002) in RA patients although the exact mechanisms underlying its antirheumatic effects 
are not fully understood (Dolhain et al., 1998; Gerards et al., 2003). Currently, MTX is used 
as an anchor drug in RA therapy. However, MTX also causes adverse effects, such as 
myelosuppression and interstitial pneumonitis because it is an anticancer agent. Therefore, 
it is necessary to design a safe and effective dosing protocol for MTX treatment. 
3.2.1 Basic study 
In recent years, it has been stated that cytokines are an important factor in the pathogenesis 
of RA (Chu et al., 1991) and that the levels of proinflammatory cytokines are increased in RA 
patients. Blood cytokine levels show circadian rhythms in RA patients (Arvidson et al., 1997; 
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Sulli et al., A, 2002), and these rhythms correspond to those of morning stiffness. We 
consider that RA therapy associated with cytokine circadian rhythms might be more 
effective than the RA therapy used commonly in clinical practice. 
In previous studies, we revealed that the circadian rhythms of SAA and TNF- levels, which 
peak in the light phase, were maintained after RA onset in CIA and MRL/lpr mice (Fig. 6 
and 9; To et al., 2009 and 2011). Based on the circadian rhythms of plasma SAA and TNF- 
levels in MRL/lpr mice (Fig. 9), MTX was administered three times a week for 2 weeks at 
1:00 or 13:00, when the TNF- level begins to decrease and increase, respectively. The TNF- 
levels did not differ between the control and 13:00-treated groups, although they were 
significantly lower in the 1:00-treated group than in the control group (P < 0.05). The SAA 
concentration in the 1:00-treated group was significantly lower than those in the control and 
13:00-treated groups (vs. control: P < 0.01, vs. 13:00: P < 0.05; Fig. 9) (To et al., 2011).  
In the CIA model, clear circadian rhythms in SAA and TNF-levels were observed, with 
higher levels seen in the morning and lower levels observed at night (Fig. 6; To et al., 2009), 
and MTX was intraperitoneally injected at 5:00 or 17:00 every 7 days for 3 weeks. The 5:00-
treated group displayed significantly reduced arthritis scores compared with the control 
and 17:00-treated groups (P < 0.01, respectively; Fig. 9). On the other hand, the arthritis 
scores of the 17:00-treated group did not differ from those of the control group for the entire 
study period in mice. 
 
 
Fig. 9. Influence of MTX dosing time on antirheumatic effects 
In these studies, the dosing time-dependent changes in the SAA level corresponded to 
identical changes in the TNF- level. It is likely that the SAA level is reduced due to a 
decrease in the TNF- concentration after MTX administration from midnight to early 
morning. In addition, arthritis and inflammation were reduced in the dark phase, when the 
plasma TNF- concentration began to increase, in both the CIA model and MRL/lpr mice. 
These findings reveal that the therapeutic effects of MTX treatment can be improved by 
administering MTX when the serum TNF- level begins to increase. 
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MTX causes myelosuppression and is used as an antitumor drug. It is reported that the 
toxicity caused by MTX varies significantly in mice depending on the dosing time (Ohdo et 
al., 1997). In our studies using CIA mice, the MTX dosing groups showed no significant 
decreases in their leukocyte counts compared with the control group. In RA therapy, MTX is 
used at very low doses compared with those used in cancer chemotherapy. Its 
chronotoxicity was studied using 400 mg/kg of MTX to estimate the toxicity of MTX as an 
antitumor drug (Ohdo et al., 1997). However, no adverse effects were observed in our 
studies because only 60 mg/kg of MTX was administered to mice. Thus, MTX may reduce 
plasma TNF- levels by suppressing transcriptional activity rather than suppressing 
lymphocyte proliferation. 
 
 
Fig. 10. Plasma concentration of MTX after drug administration at 5:00 or 17:00 (redrawn 
from the data of To et al., 2009) 
To clarify the mechanism underlying dosing time dependency, we investigated the 
influence of dosing time on the pharmacokinetics of MTX. MTX is largely excreted in urine. 
Both renal blood flow and the glomerular filtration rate have been found to follow circadian 
rhythms, with a peak during the active period in animals. The MTX concentration was 
expected to be higher in the 17:00-treated group than in the 5:00-treated group since MTX 
was administered during the inactive period. In our study, the plasma MTX concentrations 
at 0.5 and 2 hour after MTX injection in the 17:00 group were significantly higher than those 
in the 5:00 group (0.5 hour: P < 0.05, 2 hour: P < 0.01; Fig. 10). On the other hand, the 5:00 
group showed significantly higher plasma MTX levels than the 17:00 group at 4, 6, and 8 
hour (4 hour: P < 0.01, 6 hour: P < 0.01, 8 hour: P < 0.05; Fig. 10). However, the area under 
the plasma-time concentration curve (AUC) was 23,622 g/ml/hr at 5:00 and 32,305 
g/ml/hr at 17:00. The AUC in the 17:00-treated group, which showed no decrease in the 
arthritis score, was 1.28-fold higher than that in the 5:00-treated group, which had a 
significantly arthritis reduced score. Thus, no relationship was detected between the 
concentration of MTX and its efficacy. It was reported in previous studies that there were no 
dosing time-dependent changes in MTX pharmacokinetics in patients with cancer  
(Balis et al., 1989; Robinson et al., 1989). Moreover, no difference was noted in MTX 
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pharmacokinetics according to the injection time when MTX was administered to RA 
patients intramuscularly at 10:00 or 18:00 (Carpentier et al., 1998).  
From the results of our studies and the circadian cycles of cytokines in RA patients, it is 
thought that MTX has a significant dosing-time-dependent anti-inflammatory action and 
that this effect might be due to the circadian rhythms of cytokine levels rather than the 
pharmacokinetics of MTX. 
It was shown that there were daily variations in the plasma SAA and TNF- concentrations 
in CIA and MRL/lpr mice after the onset of RA and that their arthritis score and SAA and 
TNF- levels were relieved after the administration of MTX at specific times in 
synchronization with the circadian rhythm of TNF-. Therefore, we consider that choosing 
an optimal dosing time associated with the circadian rhythm of RA symptoms could lead to 
effective MTX treatment for RA. 
3.2.2 Clinical study 
From our studies in RA model animals, we anticipated that higher therapeutic effects could 
be achieved with chronotherapy compared with the current treatment schedule, in which 
MTX is administered during the night. In RA patients, pain and stiffness are accentuated in 
the early morning, and proinflammatory cytokines show circadian rhythms that peak from 
midnight to early morning (Crofford et al., 1997; Perry et al., 2009). Based on our findings in 
animal studies and the circadian TNF- rhythms of RA patients, we changed the dosing 
schedules of RA patients from the standard MTX schedule, in which MTX is administered 
three times a week (day 1: after breakfast and supper, day 2: after breakfast only), to a 
chronotherapy schedule, in which the dose and number of doses per week were not 
changed, but MTX was administered once a day after supper, to examine whether a dosing-
time dependency of the therapeutic effects of MTX treatment could be detected in Japanese 
RA patients. The disease activity score (DAS) 28, modified health assessment questionnaire 
(MHAQ) score, and adverse effects were assessed. DAS28 is a composite score based on 
tender and swollen joint counts (28 joints), the patient’s global assessment of their disease 
activity (100 mm Visual Analog Scale (VAS): 0 = no activity, 100 = extreme activity), and the 
CRP level. DAS28 values were calculated as follows: 
DAS28 (CRP) = 0.56 x √(TJC28) + 0.28 x √(SJC28) + 0.014 x GH + 0.36 x ln(CRP+1) + 0.96, 
where TJC = tender joint count, SJC = swollen joint count, GH = general health, and CRP = 
CRP level in mg/l. A score of ≥ 4.1 indicates high disease activity, a score > 2.7 and ≤ 4.1 
indicates moderate disease activity, a score < 2.7 indicates low disease activity, and a score < 
2.3 indicates disease remission (van Gestel et al., 1996). The European league against 
rheumatism (EULAR) response states were classified as follows: good responders were 
patients displaying an improvement of > 1.2 and a present score of ≤ 2.7; moderate 
responders were patients displaying an improvement of > 0.6 and ≤ 1.2 and a present score 
of ≤ 4.1, or an improvement of > 1.2 and a present score of > 4.1; and non-responders were 
any patients displaying an improvement of ≤ 0.6 or patients displaying an improvement of > 
0.6 and ≤ 1.2 and a present score of > 4.1 (Fransen et al., 2005).  
The chronotherapy administered MTX after supper proved highly effective despite the dose 
and the number of doses remaining the same, although many patients did not derive a 
therapeutic benefit from the therapy. As the half-life of MTX is about 2 hours, the MTX had 
disappeared from the plasma by 10 hours after its administration. Therefore, it was thought 
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that the plasma concentration produced by administrating MTX after supper was 
insufficient. We therefore administered MTX before bedtime once a day to a patient in 
whom MTX was ineffective in the previous study. Consequently, the DAS28 of the patient 
decreased from 5.45 (4 months) to 3.25 (7 months) over  the study (moderate response) 
(Fig.11). From this result, it was considered that a higher therapeutic effect can be achieved 
by administrating MTX before bedtime compared with after supper. 
 
 
Fig. 11. Influence of MTX chronotherapy on DAS28 score (case data) 
We studied the effects of MTX chronotherapy before bedtime, and the dose and the 
number of doses per week were not changed. Twenty-two rheumatoid arthritis patients 
between 41 and 78 years of age were enrolled, and 77% received MTX chronotherapy for 
the entire 3 months of the study. Fig. 12 shows the change in DAS28 in a female RA 
patient to whom MTX was administered at bedtime. After the start of the chronotherapy, 
her DAS28 value was markedly decreased by 1.5 at only one month, and the effect was 
maintained throughout the 3 months of the study. In particular, all of her joint swelling 
disappeared, and the tenderness in many of her joints was relieved after the 
chronotherapy. 
The chronotherapy improved the DAS28 score in 14 of 17 patients (82.4%), and the mean 
DAS28 value was significantly decreased by 0.460 at one month, 0.506 at two months, and 
0.521 at three months after the start of the chronotherapy (P < 0.05 and P < 0.01, 
respectively) (Fig. 13; To et al., 2011). In particular, despite the dose and the number of doses 
remaining the same, 23.5% of patients attained clinical remission. DAS28 is calculated from 
the following 4 parameters: the tender and swollen joint counts, the patient’s global 
assessment of disease activity, and the CRP concentration. The median tender joint count 
changed little throughout the study. On the other hand, the swollen joint count was 
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markedly decreased in all patients after 3 months chronotherapy. The CRP level continued 
to improve throughout the 3 month study period and had improved by 64.2% after the 
chronotherapy compared with the baseline. The patient’s global assessment of disease 
activity is susceptible to patient bias because each patient evaluates their own degree of 
illness. In this study, the patients understood that the method of MTX administration had 
changed. The patient’s global assessment of disease activity did not show definite changes, 
even though a placebo effect of the chronotherapy was anticipated. Therefore, it was 
considered that the placebo effect did not contribute to the observed significant decrease in 
the DAS28 score. 
 
 
Fig. 12. Influence of MTX chronotherapy (before bedtime) on DAS28 score (case data) 
The MHAQ is used to estimate the functional capacity of RA patients. It assesses the ability 
of patients to perform daily activities using eight questions. The final MHAQ score is the 
mean score of the eight questions and ranges from 0 to 3, with higher levels reflecting 
greater disability (Pincus et al., 1983). It was revealed that chronotherapy improved the 
functional capacity of the RA patients although we could not clarify the factors responsible 
for the improvement in the MHAQ score from the data obtained in this study. Almost all 
patients had mild leukopenia although the incidence of leukopenia higher than Grade 1 
increased from 11.8% to 23.5% throughout the study. Moreover, there were no severe 
adverse effects in 17 patients.  
From these results, it was demonstrated that MTX chronotherapy is safe and markedly 
improves the disease activity and functional capacity of RA patients. 
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Fig. 13. Efficacy of 3 months MTX treatment in Japanese RA patients (redrawn from the data 
of To et al., 2011) 
4. Conclusion 
RA is an autoimmune disorder of unknown etiology, and morning stiffness is a well-known 
characteristic of the condition. Inflammatory responses show circadian rhythms in RA 
patients, and these rhythms correspond to that of morning stiffness. Moreover, it is 
considered that cytokine rhythms contribute to the rhythm of inflammatory responses since 
the circadian rhythms of inflammatory responses and cytokines are similar. The symptoms 
of RA such as disease activity and the patients' functional capacity, arthritis, pain, etc. were 
relieved after the administration of anti-antirheumatic drugs such as MTX, steroids, NSAID, 
etc. at specific times in synchronization with the circadian rhythm of cytokines and the 
inflammatory response. Choosing an optimal dosing time that is associated with the 
circadian rhythms of RA symptoms is, therefore, expected to lead to more effective medical 
therapy for RA (Fig. 14). 
Presently, we are performing basic and clinical studies to prove the utility of chronotherapy 
involving various anti-antirheumatic drugs. From these studies, we hope to be able to 
propose safe and effective RA therapies. Furthermore, the mechanism regulating the 
generation of circadian rhythms in RA is being studied. It is expected that new drugs 
targeting RA will be discovered and that new RA therapies that regulate the 
abovementioned circadian rhythms will be developed once the mechanism responsible for 
their generation has been clarified. 
www.intechopen.com
 Chronobiology of and Chronotherapy for Rheumatoid Arthritis 
 
563 
 
Fig. 14. Concept of chronotherapy 
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